Genprex's Reqorsa® Gene Therapy Shows Promising Biomarker Data at 2026 ASCO Annual Meeting

Promising Advances in Lung Cancer Treatment with Genprex's Reqorsa® Gene Therapy

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Genprex, Inc. showcased new findings from clinical studies that underscore the potential of their gene therapy, Reqorsa® (quaratusugene ozeplasmid), to significantly alter treatment pathways for lung cancer. The research reveals how particular biomarkers can be instrumental in predicting patient responses and optimizing treatment plans.

The Importance of Biomarkers

The clinical data presented suggests that high Trop-2 levels along with low PTEN levels correlate positively with longer Progression Free Survival (PFS) in patients suffering from Non-Small Cell Lung Cancer (NSCLC). This makes them crucial biomarkers for personalizing therapy and enhancing treatment outcomes. Ryan Confer, President and CEO of Genprex, highlighted that these findings substantiate earlier preclinical evidence and represent a major leap toward individualized cancer treatment.

Study Insights

The findings were derived from Genprex’s Acclaim clinical trials, where patient samples were rigorously analyzed to determine the levels of Trop-2 and PTEN. Results showed that in patients with NSCLC, Trop-2 H-scores exceeding 100 were statistically significant in correlating with prolonged PFS (p=0.05), while PTEN H-scores below 100 also demonstrated a similar association (p=0.03). However, similar trends were not observed in Small Cell Lung Cancer (SCLC) patients, whose Trop-2 scores were low and thus not evaluable.

Preclinical studies had signaled a potential link between these protein expressions and treatment response, guiding the exploration in actual patient samples. The analysis utilized monoclonal antibodies for immunohistochemistry on archived tumor sections, marking a progressive step forward in translational medicine for cancer treatment.

Looking Ahead

Mark S. Berger, Chief Medical Officer at Genprex, expressed enthusiasm for further studies that will delve into the significance of high Trop-2 expression as a predictive biomarker for Reqorsa®. The ongoing efforts to refine patient selection criteria based on these biomarkers aim to provide more concrete data that can enhance clinical results.

In addition to the exploration of biomarkers, the Acclaim clinical trials evaluate the efficacy of Reqorsa® in combination with other treatment regimens, including AstraZeneca's Tagrisso® and Genentech's Tecentriq®, reinforcing the therapy's versatile application in various stages and types of lung cancer.

Conclusion

Genprex's commitment to pioneering innovative treatments through gene therapy shines through its latest findings presented at ASCO 2026. As they strive to integrate biomarker data into clinical practice, there is great hope for improved patient outcomes and advancement of precision medicine in oncology. The future of lung cancer treatment could very well depend on therapies like Reqorsa® and the intelligent use of biomarkers to sculpt personalized treatment landscapes.

For more updates on Genprex and their ongoing clinical research, investors and the public can follow their announcements and progress on their official website and social media platforms.